Aveo Pharmaceuticals (AVEO) 1.03 $AVEO
Will AVEO Pharmaceuticals (AVEO) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 4:52AM CDT
As of late, it has definitely been a great time to be an investor AVEO Pharmaceuticals, Inc. (AVEO)
AVEO: 1.03 (-0.03)
AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
BusinessWire - Thu May 26, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
AVEO: 1.03 (-0.03)
AVEO Announces Closing of Private Placement and Amended Term Loan to Fund Pivotal TIVO-3 Trial and Combination PD-1 Trial of Tivozanib in Renal Cell Cancer
BusinessWire - Wed May 18, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it has closed its previously announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share of common stock, at a price of $0.965 per unit, for gross proceeds of approximately $17 million. The transaction was led by New Enterprise Associates and included New Leaf Venture Partners and Perceptive Advisors, among other institutional investors. Certain members of the Company's management team and Board of Directors also participated in the financing.
AVEO: 1.03 (-0.03)
AVEO Announces $17 Million Private Placement
BusinessWire - Fri May 13, 8:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it entered into a securities purchase agreement for a private placement with a select group of qualified institutional buyers, institutional accredited investors and accredited investors. The private placement will consist of 17,642,482 units, at a price of $0.965 per unit, for gross proceeds of approximately $17 million, before deducting placement agent fees and estimated offering expenses. Each unit consists of one share of AVEO's common stock and a warrant to purchase one share of AVEO's common stock. The warrants will have an exercise price of $1.00 per share and will be exercisable for a period of five years from the date of issuance. The closing of the financing is expected to take place on or about May 18, 2016, and is subject to standard closing conditions. AVEO expects to use the proceeds from the financing to fund its U.S. pivotal Phase 3 trial of tivozanib, to support a combination trial of tivozanib with a PD-1 inhibitor and for general corporate purposes.
AVEO: 1.03 (-0.03)
AVEO Q1 Loss In Line with Expectation, Tivozanib in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:19AM CDT
AVEO Pharmaceuticals' (AVEO) first-quarter 2016 loss of 13 cents per share came in line with the Zacks Consensus Estimate.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), AVEO: 1.03 (-0.03), BMY: 72.65 (-0.08)
AVEO reports 1Q loss
Automated Insights - Tue May 10, 3:13PM CDT
CAMBRIDGE, Mass. (AP) _ AVEO Pharmaceuticals Inc. (AVEO) on Tuesday reported a loss of $7.7 million in its first quarter.
AVEO: 1.03 (-0.03)
AVEO Oncology Reports First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Tue May 10, 3:01PM CDT
AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2016.
AVEO: 1.03 (-0.03)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 38.40 (-0.47), BIIB: 246.13 (-4.33), CNAT: 2.02 (-0.11), AMGN: 154.78 (-2.00), RPRX: 1.70 (-0.08), JNJ: 117.01 (+0.01), GILD: 84.45 (-1.32), GWPH: 89.69 (+0.24), GERN: 2.77 (-0.04), AVEO: 1.03 (-0.03), ICPT: 150.66 (-3.56), AGIO: 50.35 (-5.87), NVS: 78.94 (-1.57)
Will AVEO Pharmaceuticals (AVEO) Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:42PM CDT
AVEO Pharmaceuticals (AVEO) is expected to report first-quarter 2016 results on Mar 5.
ZTS: 47.39 (-0.75), OPHT: 56.33 (+0.17), AVEO: 1.03 (-0.03), NVS: 78.94 (-1.57)
AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH
BusinessWire - Mon May 02, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company's potent inhibitory antibody specific to Notch 3. These patent applications are the second set of applications related to AV-353 and the Company's Notch 3 antibody program.
AVEO: 1.03 (-0.03)
AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:25AM CDT
AVEO Pharmaceuticals (AVEO) struck an exclusive collaboration and license agreement granting CANbridge Life Sciences rights to AV-203 outside North America.
BIIB: 246.13 (-4.33), OPHT: 56.33 (+0.17), AVEO: 1.03 (-0.03), NVS: 78.94 (-1.57)
AVEO Q4 Loss Narrower than Expected, Tivozanib in Focus
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 9:00AM CDT
AVEO Pharmaceuticals (AVEO) reported a narrower-than-expected fourth-quarter 2015 loss of 11 cents per share.
AVEO: 1.03 (-0.03), ANIK: 49.16 (+0.24), NVS: 78.94 (-1.57)
AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4
Zacks Equity Research - Zacks Investment Research - Tue Mar 15, 8:21AM CDT
AVEO Pharmaceuticals (AVEO) reported narrower-than-expected fourth quarter loss of 11 cents per share.
AVEO: 1.03 (-0.03)
AVEO Oncology Reports Full Year 2015 Financial Results and Provides Business Update
BusinessWire - Tue Mar 15, 6:30AM CDT
AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2015 and provided a business update.
AVEO: 1.03 (-0.03)
AVEO to Present at the 28th Annual ROTH Conference
BusinessWire - Wed Mar 09, 6:00AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 28th Annual ROTH Conference on Wednesday, March 16, 2016, at 9:00 a.m. Pacific Time. The conference is being held at The Ritz Carlton Hotel in Dana Point, CA.
AVEO: 1.03 (-0.03)
Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), ARQL: 1.78 (unch), LLY: 73.95 (-0.48), GSK: 40.93 (-1.13), ONTY: 1.21 (+0.02), MDVN: 60.01 (-0.09), MRK: 56.81 (-0.37), AZN: 27.97 (-0.99), AVEO: 1.03 (-0.03), GALE: 2.08 (+0.10), PBYI: 33.41 (-0.43), NVS: 78.94 (-1.57), KPTI: 8.53 (-0.60), XLRN: 35.44 (+0.94), EXEL: 7.38 (+0.01)
Will AVEO (AVEO) Surprise Estimates in Q4 Earnings Again?
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 3:45PM CST
AVEO Pharmaceuticals (AVEO), which is expected to report fourth-quarter 2015 results on Mar 4, had recorded a positive earnings surprise of 200% last quarter.
BDSI: 2.67 (-0.18), OPHT: 56.33 (+0.17), AVEO: 1.03 (-0.03), NVS: 78.94 (-1.57)
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 27.97 (-0.99), ACH: 7.60 (-0.13), CYTR: 2.32 (-0.03), AVEO: 1.03 (-0.03), ARQL: 1.78 (unch), CTIC: 0.43 (-0.01), ARRY: 3.51 (-0.01)
Global Liver Cancer Pipeline Review, H2 2015 - 150+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j6swm/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Liver CancerOverview - Therapeutics Development - Pipeline Products for Liver Cancer- Overview - Pipeline Products for Liver Cancer- Comparative Analysis - Liver Cancer- Therapeutics under Development by Companies - Liver Cancer- Therapeutics under Investigation by Universities/Institutes - Liver Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Liver Cancer- Products under Development by Companies - Liver Cancer- Products under Investigation by Universities/Institutes - Liver Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - American Gene Technologies International Inc. - Amgen Inc. - AndroScience Corporation - APAvadis Biotechnologies Srl - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - BioCancell Ltd - Biogazelle - Bioneer Corporation - BioStar Pharmaceuticals, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5j...ver_cancer
BPMC: 19.65 (-0.87), BSPM: 3.86 (+0.53), ADRO: 11.99 (-0.43), ARWR: 5.85 (-0.14), ARQL: 1.78 (unch), AMGN: 154.78 (-2.00), CASI: 1.31 (-0.08), BMY: 72.65 (-0.08), CLBS: 0.53 (unch), AAAP: 31.26 (-0.67), CANF: 2.81 (-0.05), ABUS: 3.60 (-0.33), AZN: 27.97 (-0.99), AVEO: 1.03 (-0.03), ABBV: 61.00 (+0.25), XLRN: 35.44 (+0.94), ARRY: 3.51 (-0.01)
Will AVEO Pharmaceuticals (AVEO) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 4:52AM CDT
As of late, it has definitely been a great time to be an investor AVEO Pharmaceuticals, Inc. (AVEO)
AVEO: 1.03 (-0.03)
AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
BusinessWire - Thu May 26, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
AVEO: 1.03 (-0.03)
AVEO Announces Closing of Private Placement and Amended Term Loan to Fund Pivotal TIVO-3 Trial and Combination PD-1 Trial of Tivozanib in Renal Cell Cancer
BusinessWire - Wed May 18, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it has closed its previously announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share of common stock, at a price of $0.965 per unit, for gross proceeds of approximately $17 million. The transaction was led by New Enterprise Associates and included New Leaf Venture Partners and Perceptive Advisors, among other institutional investors. Certain members of the Company's management team and Board of Directors also participated in the financing.
AVEO: 1.03 (-0.03)
AVEO Announces $17 Million Private Placement
BusinessWire - Fri May 13, 8:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it entered into a securities purchase agreement for a private placement with a select group of qualified institutional buyers, institutional accredited investors and accredited investors. The private placement will consist of 17,642,482 units, at a price of $0.965 per unit, for gross proceeds of approximately $17 million, before deducting placement agent fees and estimated offering expenses. Each unit consists of one share of AVEO's common stock and a warrant to purchase one share of AVEO's common stock. The warrants will have an exercise price of $1.00 per share and will be exercisable for a period of five years from the date of issuance. The closing of the financing is expected to take place on or about May 18, 2016, and is subject to standard closing conditions. AVEO expects to use the proceeds from the financing to fund its U.S. pivotal Phase 3 trial of tivozanib, to support a combination trial of tivozanib with a PD-1 inhibitor and for general corporate purposes.
AVEO: 1.03 (-0.03)
AVEO Q1 Loss In Line with Expectation, Tivozanib in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:19AM CDT
AVEO Pharmaceuticals' (AVEO) first-quarter 2016 loss of 13 cents per share came in line with the Zacks Consensus Estimate.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), AVEO: 1.03 (-0.03), BMY: 72.65 (-0.08)
AVEO reports 1Q loss
Automated Insights - Tue May 10, 3:13PM CDT
CAMBRIDGE, Mass. (AP) _ AVEO Pharmaceuticals Inc. (AVEO) on Tuesday reported a loss of $7.7 million in its first quarter.
AVEO: 1.03 (-0.03)
AVEO Oncology Reports First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Tue May 10, 3:01PM CDT
AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2016.
AVEO: 1.03 (-0.03)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 38.40 (-0.47), BIIB: 246.13 (-4.33), CNAT: 2.02 (-0.11), AMGN: 154.78 (-2.00), RPRX: 1.70 (-0.08), JNJ: 117.01 (+0.01), GILD: 84.45 (-1.32), GWPH: 89.69 (+0.24), GERN: 2.77 (-0.04), AVEO: 1.03 (-0.03), ICPT: 150.66 (-3.56), AGIO: 50.35 (-5.87), NVS: 78.94 (-1.57)
Will AVEO Pharmaceuticals (AVEO) Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:42PM CDT
AVEO Pharmaceuticals (AVEO) is expected to report first-quarter 2016 results on Mar 5.
ZTS: 47.39 (-0.75), OPHT: 56.33 (+0.17), AVEO: 1.03 (-0.03), NVS: 78.94 (-1.57)
AVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH
BusinessWire - Mon May 02, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company's potent inhibitory antibody specific to Notch 3. These patent applications are the second set of applications related to AV-353 and the Company's Notch 3 antibody program.
AVEO: 1.03 (-0.03)
AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:25AM CDT
AVEO Pharmaceuticals (AVEO) struck an exclusive collaboration and license agreement granting CANbridge Life Sciences rights to AV-203 outside North America.
BIIB: 246.13 (-4.33), OPHT: 56.33 (+0.17), AVEO: 1.03 (-0.03), NVS: 78.94 (-1.57)
AVEO Q4 Loss Narrower than Expected, Tivozanib in Focus
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 9:00AM CDT
AVEO Pharmaceuticals (AVEO) reported a narrower-than-expected fourth-quarter 2015 loss of 11 cents per share.
AVEO: 1.03 (-0.03), ANIK: 49.16 (+0.24), NVS: 78.94 (-1.57)
AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4
Zacks Equity Research - Zacks Investment Research - Tue Mar 15, 8:21AM CDT
AVEO Pharmaceuticals (AVEO) reported narrower-than-expected fourth quarter loss of 11 cents per share.
AVEO: 1.03 (-0.03)
AVEO Oncology Reports Full Year 2015 Financial Results and Provides Business Update
BusinessWire - Tue Mar 15, 6:30AM CDT
AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2015 and provided a business update.
AVEO: 1.03 (-0.03)
AVEO to Present at the 28th Annual ROTH Conference
BusinessWire - Wed Mar 09, 6:00AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 28th Annual ROTH Conference on Wednesday, March 16, 2016, at 9:00 a.m. Pacific Time. The conference is being held at The Ritz Carlton Hotel in Dana Point, CA.
AVEO: 1.03 (-0.03)
Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), ARQL: 1.78 (unch), LLY: 73.95 (-0.48), GSK: 40.93 (-1.13), ONTY: 1.21 (+0.02), MDVN: 60.01 (-0.09), MRK: 56.81 (-0.37), AZN: 27.97 (-0.99), AVEO: 1.03 (-0.03), GALE: 2.08 (+0.10), PBYI: 33.41 (-0.43), NVS: 78.94 (-1.57), KPTI: 8.53 (-0.60), XLRN: 35.44 (+0.94), EXEL: 7.38 (+0.01)
Will AVEO (AVEO) Surprise Estimates in Q4 Earnings Again?
Zacks Equity Research - Zacks Investment Research - Wed Mar 02, 3:45PM CST
AVEO Pharmaceuticals (AVEO), which is expected to report fourth-quarter 2015 results on Mar 4, had recorded a positive earnings surprise of 200% last quarter.
BDSI: 2.67 (-0.18), OPHT: 56.33 (+0.17), AVEO: 1.03 (-0.03), NVS: 78.94 (-1.57)
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 27.97 (-0.99), ACH: 7.60 (-0.13), CYTR: 2.32 (-0.03), AVEO: 1.03 (-0.03), ARQL: 1.78 (unch), CTIC: 0.43 (-0.01), ARRY: 3.51 (-0.01)
Global Liver Cancer Pipeline Review, H2 2015 - 150+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j6swm/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Liver CancerOverview - Therapeutics Development - Pipeline Products for Liver Cancer- Overview - Pipeline Products for Liver Cancer- Comparative Analysis - Liver Cancer- Therapeutics under Development by Companies - Liver Cancer- Therapeutics under Investigation by Universities/Institutes - Liver Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Liver Cancer- Products under Development by Companies - Liver Cancer- Products under Investigation by Universities/Institutes - Liver Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - American Gene Technologies International Inc. - Amgen Inc. - AndroScience Corporation - APAvadis Biotechnologies Srl - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - BioCancell Ltd - Biogazelle - Bioneer Corporation - BioStar Pharmaceuticals, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5j...ver_cancer
BPMC: 19.65 (-0.87), BSPM: 3.86 (+0.53), ADRO: 11.99 (-0.43), ARWR: 5.85 (-0.14), ARQL: 1.78 (unch), AMGN: 154.78 (-2.00), CASI: 1.31 (-0.08), BMY: 72.65 (-0.08), CLBS: 0.53 (unch), AAAP: 31.26 (-0.67), CANF: 2.81 (-0.05), ABUS: 3.60 (-0.33), AZN: 27.97 (-0.99), AVEO: 1.03 (-0.03), ABBV: 61.00 (+0.25), XLRN: 35.44 (+0.94), ARRY: 3.51 (-0.01)
